Centene Options Signal Unusual Caution One Week After Q3 Beat

Centene has had a quieter week since its Q3 earnings on October 27, but the options market has not settled down with the stock.

The clearest shift this week is in options positioning. Put demand has climbed well above its recent norm: the put/call ratio reached 0.79 on November 3, nearly at its 52-week high of 0.79, and running more than two standard deviations above its 20-day average of 0.54. That is a sharp turn from the previous month, when the ratio sat in the 0.44 to 0.47 range throughout October. The jump started in the final days of October, immediately after the earnings release, and has held. Options traders appear to be hedging against further downside even as the stock recovered 1.4% on Tuesday to close at $67.48.

The short-selling picture tells a much quieter story. Short interest now stands at 2.2% of the free float, down 5.4% on the week and nearly 18% lower than a month ago. The lending market is entirely relaxed: availability is at 6,215%, meaning there are roughly 62 shares available to borrow for every share currently borrowed, close to the most comfortable the lending pool has been all year. Borrowing costs have fallen 25% over the week to just 0.21%. For all the caution in the options market, there is no comparable pressure from short sellers, the two signals diverge quite sharply.

The Street's response to the Q3 print has been constructive, adding a further layer of interest to the gap between short and options positioning. Building on the wave of target raises on October 28, Truist lifted its target to $82 from $80 on November 2 and reiterated Buy, while Wells Fargo raised to $75 from $69 and JP Morgan moved to $75 from $67, both keeping neutral ratings. Across all recent moves, the direction is uniform: every firm that revised has raised. The consensus mean now stands at $74.50, implying roughly 10% upside from Tuesday's close. Notably, the bull case centres on the Medicaid healthcare benefit ratio improvement to 93.4% and Medicare membership of 1.01 million, while bears point to the decline in low-cost Silver plan positions from 55% to a projected 42% and a commercial HBR that came in below expectations. EV/EBITDA has edged down modestly over the past 30 days, and the stock trades at 12.3 times earnings, with EPS momentum ranking in the 88th percentile on a 30-day basis.

Institutional ownership is concentrated at the top. BlackRock reported 8.4% as of September 30, adding 1.7 million shares in the period. Wellington's last reported position, as of August, showed a large addition of nearly 10.8 million shares, though that filing predates recent price action. Columbia Management added 2.3 million shares as of September 30. The register shows no activist 13D filings. The most significant insider activity in recent months was the General Counsel's sale of roughly $6.9 million worth of stock across two transactions in August, the largest directional move in the 90-day window. Net insider selling over the 90 days through October 15 came to approximately $6.9 million, with no open-market purchases recorded in that period.

The stock slipped 1.8% on the week, slightly weaker than the median for its closest peers. ELV fell a comparable 1.8%, UNH dropped 1.4%, while MOH bucked the group with a 4.2% gain. The next earnings event is scheduled for February 2, 2027, leaving roughly 90 days before the next formal update on where Medicaid rates and Silver plan composition land. The gap between the Street's freshly-raised targets and the defensive options positioning is the most live tension in the stock right now.